News
The Irish company Cosmo Pharmaceuticals N.V., which specializes in innovative methods of treating certain gastrointestinal diseases, is the owner of a unique patented matrix technology MMX®.
Its essence is in the coating of tablets with pH-resistant acrylic copolymers, which provide after taking the drug controlled release of the active pharmaceutical ingredient (API) along the entire length of the colon in a slow and controlled manner.
This process ensures the application of active pharmaceutical ingredients to the entire length of the colon. In addition, the company was one of the first to use artificial intelligence to detect colorectal polyps. At this stage, GI Genius ™ - approved in Europe, Australia, the United Arab Emirates and Israel.
The trial required for approval in the United States began in the first quarter of 2020. In February 2020, the company announced the very positive results of the first prospective clinical trial of GI Genius ™, initiated by the researcher. This study demonstrates that GI Genius ™ allows the endoscopist to detect a significantly higher proportion of patients with adenomas, as well as more adenomas per patient.